MBX Biosciences, an Indiana University faculty-created startup that develops peptide therapies for the treatment of endocrine and metabolic diseases, raised $163.2 million in its U.S. initial public offering. The company’s peptides are based on chemistry developed by a research team led by Richard DiMarchi, scientific cofounder of MBX Biosciences and Distinguished Professor of Chemistry in… Read more »